The paradigm of personalized therapy in oncology (Q37954671)

25 August 2017

The paradigm of personalized therapy in oncology (English)

1 reference

25 August 2017

Giampietro Gasparini

1

1 reference

PubMed ID

22073968

25 August 2017

Raffaele Longo

series ordinal

2

1 reference

PubMed ID

22073968

25 August 2017

language of work or name

English

0 references

publication date

11 November 2011

1 reference

Expert Opinion on Therapeutic Targets

25 August 2017

1 reference

25 August 2017

16 Suppl 1

1 reference

25 August 2017

S7-16

1 reference

Hallmarks of Cancer: The Next Generation

25 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.637921

The biology of stem cell factor and its receptor C-kit

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.637921

Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.637921

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.637921

Approval summary: imatinib mesylate in the adjuvant treatment of malignant gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.637921

Pharmacological management of gastrointestinal stromal tumours: an update on the role of sunitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.637921

Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.637921

Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.637921

Correlations between imatinib pharmacokinetics, pharmacodynamics, adherence, and clinical response in advanced metastatic gastrointestinal stromal tumor (GIST): an emerging role for drug blood level testing?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.637921

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.637921

New driver mutations in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.637921

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.637921

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.637921

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.637921

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.637921

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.637921

Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.637921

Lung cancer: intragenic ERBB2 kinase mutations in tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.637921

Somatic mutations of the HER2 kinase domain in lung adenocarcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.637921

PIK3CA mutation and amplification in human lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.637921

AKT plays a central role in tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.637921

Mutations of the BRAF gene in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.637921

Clinical experience to date with nilotinib in gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.637921

Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.637921

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.637921

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.637921

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.637921

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.637921

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.637921

Evolving strategies for overcoming resistance to HER2-directed therapy: targeting the PI3K/Akt/mTOR pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.637921

Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.637921

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.637921

Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.637921

Growth factor receptor interplay and resistance in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.637921

Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.637921

Letrozole versus letrozole plus Lapatinib (GW572016) in hormone-sensitive, HER2-negative operable breast cancer: a double-blind, randomized, phase II study with biomarker evaluation (EGF109077-LAP107692/LETLOB).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.637921

Preoperative chemotherapy plus lapatinib or trastuzumab or both in HER2-positive operable breast cancer (CHERLOB Trial).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.637921

Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.637921

The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.637921

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.637921

Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.637921

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.637921

Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.637921

Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.637921

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.637921

New strategies in metastatic melanoma: oncogene-defined taxonomy leads to therapeutic advances

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.637921

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.637921

Mutant BRAF melanomas--dependence and resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.637921

Parametric images via dynamic 18F-fluorodeoxyglucose positron emission tomographic data acquisition in predicting midterm outcome of liver metastases secondary to gastrointestinal stromal tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.637921

Understanding resistance to EGFR inhibitors-impact on future treatment strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.637921

Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.637921

Epigenetic modifications in double-strand break DNA damage signaling and repair

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.637921

A ceRNA hypothesis: the Rosetta Stone of a hidden RNA language?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.637921

BikDD eliminates breast cancer initiating cells and synergizes with lapatinib for breast cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.637921

A national cancer clinical trials system for targeted therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.637921

Taming the dragon: genomic biomarkers to individualize the treatment of cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2011.637921

10.1517/14728222.2011.637921

21 January 2018

Identifiers

DOI

1 reference

25 August 2017

1 reference

PubMed ID

22073968